What is KPV studied for?

KPV is a tripeptide made from lysine, proline and valine and is described as the C-terminal fragment of alpha-MSH. The supplied evidence focuses on anti-inflammatory research, especially gut and skin inflammation models. Human efficacy has not been established in the provided evidence, which is described as animal and cell-based research.

No. The supplied source states that KPV is not FDA approved and places it in a preclinical research category.

What dose is reported for KPV?

The source gives community-reported use of 200-500 mcg daily, with a broader 100-1000 mcg daily range and 1-2 times daily frequency. It also lists subcutaneous injection and oral capsules as routes. These figures are included as reported evidence only and are not validated treatment instructions.

Immune Preclinical - animal studies only

KPV

Also known as: Lys-Pro-Val, Alpha-MSH fragment

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Alpha-MSH-derived tripeptide studied in preclinical anti-inflammatory models

Status

Preclinical

Evidence level: animal studies

Typical dose

200–500mcg

Subcutaneous injection or oral capsules

Researched for

Gut inflammation, IBD, skin conditions and anti-inflammatory activity

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

KPV is a single tripeptide composed of lysine, proline and valine and is described as an alpha-MSH fragment.
The supplied evidence frames KPV as an anti-inflammatory research , mainly in gut inflammation, IBD-related models and skin-condition contexts.
Evidence status is , with animal and cell-culture findings and no provided randomized human efficacy trials.
Reported community dosing is 200-500 mcg daily, commonly 1-2 times daily, by injection or oral capsules.

How it's thought to work

KPV is described as a short alpha-MSH-derived with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a working model rather than a confirmed clinical pathway.

What the research shows

Where the research stands

The supplied research summary places KPV in a evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical research ongoing; no human clinical-trial benefit evidence was provided Not FDA approved

Typical dosing

CommunityCommunity dataset

200–500 mcg

daily

100 mcgfull range seen1,000 mcg

Community-reported dosing for anti-inflammatory research contexts involving gut and skin topics; not established clinical dosing.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

200-500 mcg daily

Preclinical research - doses from animal/in-vitro studies

Animal study doses may not translate directly to humans.

Duration: 4-8 weeks typical
Administration: Subcutaneous injection or oral capsules

Timing & administration

Best time to take

Morning, or as directed in the source context

Once daily

Food recommendation

With or without food

Why this timing?

The source favors morning timing in the context of daytime inflammation-related research use; this is a reported timing preference, not a validated clinical requirement.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated
Injection-site reactions
Transient mild flu-like symptoms
Mild gastrointestinal effects
Possible histamine release
Does not cause immunosuppression
Cancer-history contraindication claim

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

The proposed model is that KPV can enter cells through PepT1, a peptide transporter associated with intestinal uptake and reported to increase in inflamed colon tissue. Laboratory studies then link intracellular KPV with reduced NF-kB signaling and lower pro-inflammatory cytokine output, including TNF-alpha, IL-1beta and IL-6. The source also notes that KPV differs from alpha-MSH because it is not thought to rely on classic melanocortin receptor activation.

The source reports that KPV is generally well tolerated, while listing injection-site reactions, transient flu-like symptoms, mild gastrointestinal effects and possible histamine release as concerns. It also lists cautions about histamine sensitivity or MCAS, a claim that it does not cause immunosuppression and a cancer-history contraindication claim; these safety statements were not supported by human trial evidence in the input.

Sequence

H-Lys-Pro-Val-OH (KPV)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on KPV

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

KPV

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions

What is KPV studied for?

How is KPV proposed to work?

Is KPV FDA approved?

What side effects are reported for KPV?